Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Klimek

Showing results (151-160 of 161) with videos related to

Pageof 17
Sort By:
Haematologica|May 26, 2018
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemiaFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyPeter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
The Lancet. Oncology|August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.
Blood|April 30, 2024
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromesMaria Sirenko, Elsa Bernard, Maria Creignou, et al.
Blood|July 3, 2024
Molecular taxonomy of myelodysplastic syndromes and its clinical implicationsElsa Bernard, Robert P Hasserjian, Peter L Greenberg, et al.
Nature Genetics|October 27, 2020
Cancer therapy shapes the fitness landscape of clonal hematopoiesisKelly L Bolton, Ryan N Ptashkin, Teng Gao, et al.
NEJM Evidence|February 6, 2024
Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElsa Bernard, Heinz Tuechler, Peter L Greenberg, et al.
Nature Medicine|February 10, 2021
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Yasuhito Nannya, Robert P Hasserjian, et al.
Nature Medicine|May 5, 2021
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Yasuhito Nannya, Robert P Hasserjian, et al.
Pageof 17

Showing results (151-160 of 161) with videos related to

Sort By:
Pageof 17
Haematologica|May 26, 2018
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemiaFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyPeter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
The Lancet. Oncology|August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.
Blood|April 30, 2024
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromesMaria Sirenko, Elsa Bernard, Maria Creignou, et al.
Blood|July 3, 2024
Molecular taxonomy of myelodysplastic syndromes and its clinical implicationsElsa Bernard, Robert P Hasserjian, Peter L Greenberg, et al.
Nature Genetics|October 27, 2020
Cancer therapy shapes the fitness landscape of clonal hematopoiesisKelly L Bolton, Ryan N Ptashkin, Teng Gao, et al.
NEJM Evidence|February 6, 2024
Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElsa Bernard, Heinz Tuechler, Peter L Greenberg, et al.
Nature Medicine|February 10, 2021
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Yasuhito Nannya, Robert P Hasserjian, et al.
Nature Medicine|May 5, 2021
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Yasuhito Nannya, Robert P Hasserjian, et al.
Pageof 17